following a full submission considered under the end of life and orphan equivalent process:
atezolizumab (Tecentriq®) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy.
In a phase III randomised study of patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy, there was a small numerical increase in median overall survival for patients treated with atezolizumab compared with chemotherapy.
The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
This advice replaces the second line recommendation for atezolizumab SMC No 1297/18.
- Medicine name:
- atezolizumab (Tecentriq)
- SMC ID:
- As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma: − after prior platinum-containing chemotherapy, or − who are considered cisplatin ineligible
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full submission
- Not recommended
- Date advice published:
- 12 November 2018